nach oben

Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen

Erschienen in:

18.06.2018 | Originalien

Psoriasisarthritis

verfasst von: Dr. med. Johannes Resch-Passini, Dr. med. univ. Peter Spellitz

Erschienen in: Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Psoriasisarthritis präsentiert ein sehr heterogenes klinisches Bild und stellt in der täglichen Praxis große Herausforderungen an Diagnosestellung und Therapieentscheidung. Die Enthesitis dürfte eine zentrale Rolle bei dieser entzündlichen Autoimmunerkrankung spielen.

Die European League Against Rheumatism (EULAR) empfiehlt eine Treat-to-target-Vorgehensweise im Sinne einer konsequenten Therapieüberwachung und -anpassung in definierten Zeitabständen. Stufenweise soll nach dem Einsatz von nichtsteroidalen Antirheumatika (NSAR) eine Therapie mit csDMARDs und bDMARDs („conventional synthetic [cs] and biological [b] disease-modifying antirheumatic drugs“) wie TNF-alpha-Blocker, Interleukin-17- und Interleukin-12/23-Inhibitoren erfolgen. Die „Group for Research and Assessment of Psoriasis and Psoriatic Arthritis“ (GRAPPA) hingegen empfiehlt ein individuelles therapeutisches Vorgehen je nach betroffener Domäne.

Vorheriger Artikel Entzündlicher Rückenschmerz und axiale Spondyloarthritis

Nächster Artikel Mitteilungen des Magnesiumforum Bad Radkersburg

Coates LC, Ritchlin CT, Kavanaugh AF (2014) GRAPPA treatment recommendations: an update from the GRAPPA 2013 Annual Meeting. J Rheumatol 41(6):1237–1239 (Jun)CrossRefPubMed

Torre Alonso JC, Rodriguez PA, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez Larrea C (1991) Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 30(4):245–250 (Aug)CrossRefPubMed

Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK (1987) Psoriatic arthritis (PSA)—an analysis of 220 patients. Q J Med 62(238):127–141PubMed

Kane D, Stafford L, Bresnihan B, FitzGerald O (2003) A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 42(12):1460–1468CrossRef

Popescu C, Zofotă S, Bojincă V, Ionescu R (2013) Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis—cross-sectional study and literature review. J Med Life 6(4):376–382PubMedPubMedCentral

Bowes J, Ashcroft J, Dand N et al (2017) Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. Ann Rheum Dis 76(10):1774–1779 (Oct)CrossRefPubMedPubMedCentral

Khan MA (2002) Update on spondyloarthropathies. Ann Intern Med 136(12):896–907 (Jun)CrossRefPubMed

Dhir V, Aggarwal A (2013) Psoriatic arthritis: a critical review. Clin Rev Allergy Immunol 44(2):141–148 (Apr)CrossRefPubMed

Schett G, Lories RJ, D’Agostino MA, Elewaut D, Kirkham B, Soriano ER, McGonagle D (2017) Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol 13(12):731–741CrossRefPubMed

10.

Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376(10):957–970CrossRefPubMed

11.

Simon D, Faustini F, Kleyer A et al (2016) Analysis of periarticular bone changes in patients with cutaneous psoriasis without associated psoriatic arthritis. Ann Rheum Dis 75(4):660–666CrossRefPubMed

12.

Lories RJ, McInnes IB (2012) Primed for inflammation: enthesis-resident T cells. Nat Med 18(7):1018–1019 (Jul)CrossRefPubMed

13.

Moll JMH, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55–57CrossRefPubMed

14.

Polachek A, Li S, Chandran V, Gladman DD (2017) Clinical enthesitis in a prospective longitudinal psoriatic arthritis cohort: incidence, prevalence, characteristics, and outcome. Arthritis Care Res (Hoboken) 69(11):1685–1691CrossRef

15.

Eder L, Polachek A, Rosen CF, Chandran V, Cook R, Gladman DD (2017) The development of psoriatic arthritis in patients with psoriasis is preceded by a period of nonspecific musculoskeletal symptoms: a prospective cohort study. Arthritis Rheumatol 69(3):622–629CrossRefPubMed

16.

Jafri K, Bartels CM, Shin D, Gelfand JM, Ogdie A (2017) Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study. Arthritis Care Res 69(1):51–57 (Jan)CrossRef

17.

Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewé R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Cañete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75(3):499–510 (Mar)CrossRefPubMed

18.

Guyatt GH, Oxman AD, Kunz R et al (2008) Incorporating considerations of resources use into grading recommendations. BMJ 336:1170–1173CrossRefPubMedPubMedCentral

19.

Ogdie A, Schwartzman S, Husni ME (2015) Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol 27:118–126CrossRefPubMed

20.

Di Minno MND, Ambrosino P, Lupoli R et al (2015) Cardiovascular risk markers in patients with psoriatic arthritis: a meta-analysis of literature studies. Ann Med 47:346–353CrossRefPubMed

21.

Smolen JS, Braun J, Dougados M et al (2014) Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 73:6–16CrossRefPubMed

22.

Schoels M, Aletaha D, Alasti F et al (2016) Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 75(5):811–818CrossRefPubMed

23.

Coates LC, Navarro-Coy N, Brown SR et al (2013) The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord 14:101CrossRefPubMedPubMedCentral

24.

Coates LC, Moverley AR, McParland L et al (2015) Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 386(10012):2489–2498CrossRefPubMedPubMedCentral

25.

Bond SJ, Farewell VT, Schentag CT et al (2007) Predictors for radiological damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis 66:370–376CrossRefPubMed

26.

McHugh NJ, Balachrishnan C, Jones SM (2003) Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology 42:778–783CrossRefPubMed

27.

Cresswell L, Chandran V, Farewell VT et al (2011) Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis. Ann Rheum Dis 70:305–308CrossRefPubMed

28.

Brockbank JE, Stein M, Schentag CT et al (2005) Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis 64:188–190CrossRefPubMed

29.

Simon P, Pfoehler C, Bergner R et al (2012) Swollen joint count in psoriatic arthritis is associated with progressive radiological damage in hands and feet. Clin Exp Rheumatol 30:45–50PubMed

30.

Gladman DD, Mease PJ, Choy EHS et al (2010) Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther 12:R113CrossRefPubMedPubMedCentral

31.

Ramiro S, Smolen JS, Landewé R et al (2016) Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 75(3):490–498 (Mar)CrossRefPubMed

32.

Curtis JR, Beukelman T, Onofrei A et al (2010) Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis 69:43–47CrossRefPubMedPubMedCentral

33.

Ash Z, Gaujoux-Viala C, Gossec L et al (2012) A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 71:319–326CrossRefPubMed

34.

Eder L, Chandran V, Ueng J et al (2010) Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology 49:1367–1373CrossRefPubMed

35.

Eder L, Thavaneswaran A, Chandran V et al (2014) Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis. Ann Rheum Dis 73:1007–1011CrossRefPubMed

36.

Young MS, Horn EJ, Cather JC (2011) The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients. Expert Rev Clin Immunol 7(1):9–13 (Jan)CrossRefPubMed

37.

Langley RG, Elewski BE, Lebwohl M (2014) Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 371:326–338CrossRefPubMed

38.

Mease PJ, Van der Heijde D, Ritchlin CT (2017) Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 76(1):79–87CrossRefPubMed

39.

Coates LC, Kavanaugh A, Mease PJ et al (2016) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68(5):1060–1071PubMed

40.

Mease PJ, Gottlieb AB, van der Heijde D (2017) Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis 76(9):1550–1558CrossRefPubMedPubMedCentral

41.

Mease P, Hall S, FitzGerald O (2017) Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 377(16):1537–1550CrossRefPubMed

Titel: Psoriasisarthritis
verfasst von: Dr. med. Johannes Resch-Passini
Dr. med. univ. Peter Spellitz
Publikationsdatum: 18.06.2018
Verlag: Springer Vienna
Erschienen in: Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen / Ausgabe 2/2018
Print ISSN: 2412-8260
Elektronische ISSN: 2412-8287
DOI: https://doi.org/10.1007/s41970-018-0036-3

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Mitteilungen der Österreichischen Gesellschaft für Knochen und Mineralstoffwechsel (ÖGKM)

News-Screen Osteologie

News-Screen Orthopädie & Traumatologie

News-Screen Rheumatologie

Neue Osteoporose-Leitlinie und Patienteninformation

Erkrankungen des Bewegungsapparates: Diagnose und Therapie aus einer Hand